Price T Rowe Associates Inc. MD Acquires 262,690 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Price T Rowe Associates Inc. MD increased its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 23.2% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,394,637 shares of the company's stock after buying an additional 262,690 shares during the quarter. Price T Rowe Associates Inc. MD owned about 4.69% of Disc Medicine worth $88,421,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of IRON. Sterling Capital Management LLC lifted its position in Disc Medicine by 798.4% during the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after purchasing an additional 503 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after buying an additional 266 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Disc Medicine in the 4th quarter worth $235,000. Teacher Retirement System of Texas grew its holdings in shares of Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after acquiring an additional 396 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Disc Medicine during the fourth quarter valued at $309,000. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Trading Down 1.6 %

Shares of NASDAQ:IRON opened at $45.42 on Monday. Disc Medicine, Inc. has a 12 month low of $27.39 and a 12 month high of $68.73. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -11.41 and a beta of 0.77. The firm's 50-day moving average is $48.55 and its 200 day moving average is $55.13.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.08. As a group, equities analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IRON has been the subject of several recent research reports. TD Cowen assumed coverage on shares of Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating for the company. Morgan Stanley restated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Friday, March 7th. Cantor Fitzgerald lifted their target price on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. HC Wainwright restated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, Stifel Nicolaus lifted their price objective on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, January 24th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $93.80.

Insider Buying and Selling

In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $55.54, for a total transaction of $416,550.00. Following the sale, the insider now directly owns 14,035 shares of the company's stock, valued at approximately $779,503.90. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John D. Quisel sold 5,574 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $304,228.92. Following the completion of the transaction, the chief executive officer now directly owns 154,828 shares of the company's stock, valued at $8,450,512.24. The trade was a 3.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 361,690 shares of company stock valued at $19,648,094 over the last quarter. 4.24% of the stock is owned by corporate insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.